• Product name

  • Description

    Rabbit polyclonal to ADAMTS7
  • Host species

  • Specificity

    ab28557 recognizes metalloproteinase ADAMTS7.
  • Tested applications

    Suitable for: WBmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic peptide corresponding to Human ADAMTS7. Immunogen in the spacer-1 region of the C-terminus.



Our Abpromise guarantee covers the use of ab28557 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notes
    WB: 1/1,000 when using colorimetric substrates such as BCIP/NBT and 1/5,000 for chemiluminescent substrates. Predicted molecular weight: 184 kDa. This antibody recognizes the zymogen of ADAMTS7 at around 300 kD in reduced Western blots, activated or alternatively spliced forms at 180-120 kD (major bands) and breakdown products at 58-45 kD in cell lysates. EDTA/EGTA treatment of tissues or lysates is required to see latent zymogen. Dilution optimised using Chromogenic detection. Not yet tested in other applications. Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • Function

      Metalloprotease that may play a role in the degradation of COMP.
    • Tissue specificity

      Expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Detected in meniscus, bone, tendon, cartilage, synovium, fat and ligaments.
    • Sequence similarities

      Contains 1 disintegrin domain.
      Contains 1 peptidase M12B domain.
      Contains 1 PLAC domain.
      Contains 8 TSP type-1 domains.
    • Domain

      The spacer domain and the TSP type-1 domains are important for a tight interaction with the extracellular matrix.
      The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
    • Post-translational

      N-glycosylated. Can be O-fucosylated by POFUT2 on a serine or a threonine residue found within the consensus sequence C1-X(2)-(S/T)-C2-G of the TSP type-1 repeat domains where C1 and C2 are the first and second cysteine residue of the repeat, respectively. Fucosylated repeats can then be further glycosylated by the addition of a beta-1,3-glucose residue by the glucosyltransferase, B3GALTL. Fucosylation mediates the efficient secretion of ADAMTS family members. Also can be C-glycosylated with one or two mannose molecules on tryptophan residues within the consensus sequence W-X-X-W of the TPRs. N- and C-glycosylations can also facilitate secretion. O-glycosylated proteoglycan. Contains chondroitin sulfate.
      May be cleaved by a furin endopeptidase (By similarity). The precursor is sequentially processed.
    • Cellular localization

      Secreted, extracellular space, extracellular matrix. Also found associated with the external cell surface.
    • Information by UniProt
    • Database links

    • Alternative names

      • A disintegrin and metalloprotease with thrombospondin motifs 7 preproprotein antibody
      • A disintegrin and metalloproteinase with thrombospondin motifs 7 antibody
      • A disintegrin like and metalloprotease (reprolysin type) with thrombospondin type 1 motif 7 antibody
      • A disintegrin like and metalloprotease with thrombospondin type 1 motif 7 antibody
      • ADAM metallopeptidase with thrombospondin type 1 motif 7 antibody
      • ADAM metallopeptidase with thrombospondin type 1 motif 7 preproprotein antibody
      • ADAM TS 7 antibody
      • ADAM TS7 antibody
      • ADAM-TS 7 antibody
      • ADAM-TS7 antibody
      • ADAMTS 7 antibody
      • ADAMTS-7 antibody
      • Adamts7 antibody
      • ATS7_HUMAN antibody
      • COMPase antibody
      • DKFZp434H204 antibody
      see all


    This product has been referenced in:

    • Mu Y  et al. Upregulation of ADAMTS-7 and downregulation of COMP are associated with spontaneous abortion. Mol Med Rep 19:2620-2626 (2019). Read more (PubMed: 30720083) »
    • Chan K  et al. Genetic Variation at theADAMTS7Locus is Associated With Reduced Severity of Coronary Artery Disease. J Am Heart Assoc 6:N/A (2017). IHC-P ; Human . Read more (PubMed: 29089340) »
    See all 3 Publications for this product

    Customer reviews and Q&As

    1-2 of 2 Abreviews or Q&A

    Western blot
    Human Cell lysate - whole cell (HeLa)
    Gel Running Conditions
    Reduced Denaturing (4-12%)
    Loading amount
    12 µg
    Blocking step
    Milk as blocking agent for 30 minute(s) · Concentration: 5% · Temperature: 22°C

    Abcam user community

    Verified customer

    Submitted Oct 08 2018


    Thank you for your feedback. I am sorry to hear you have experienced problems with ab28557. The quality of our products is extremely important to us, so thank you for bringing this to our attention. I can confirm that the immunogen is a "synthetic peptide based on the carboxyterminal end of human ADAMTS7 between amino acids 890-950." Therefore it should only detect isoform 1. I am not sure why a band at a lower size (95 kDa)should be detected. Could this be isolated to the type of samples tested? For example, in certian cancer cell lines, sometimes proteins can become truncated due to a high level of passaging and differential expression. Unfortunately we do no have an image of this antibody in western blot. I do have a list of suitable positive controls: HFL-1 (human fetal lung fibroblast) cell lysates RD (rhabdomyosarcoma, embryonal, epithelial) cell lysates Mouse pancreas tissue lysate Would it be possible to find out some more ifnormation about the protocol? I have attached some questions below. I look forward to your reply. Problem Choose: Non-specific band Multiple bands No signal or weak signal High background Lot number Purchase order number or preferably Abcam order number: General Information Antibody storage conditions (temperature/reconstitution etc) Description of the problem (high background, wrong band size, more bands, no band etc.) Sample (Species/Cell extract/Nuclear extract/Purified protein/Recombinant protein etc.) Sample preparation (Buffer/Protease inhibitors/Heating sample etc.) Amount of protein loaded Electrophoresis/Gel conditions (Reducing or Non-reducing gel, % of the gel etc.) Transfer and blocking conditions (Buffer/time period, Blocking agent etc.) Primary Antibody (Manufacturer/Species/Diluent/Dilution/Incubation time, Wash step) Secondary Antibody (Manufacturer/Species/Diluent/Dilution/Incubation time, Wash step) Detection method (ECL, ECLPlus etc.) Positive and negative controls used (please specify) Optimization attempts (problem solving) How many times have you tried the Western? Have you run a "No Primary" control? Yes No Do you obtain the same results every time? Yes No e.g. are the background bands always in the same place? What steps have you altered? Additional Notes: Image: We would appreciate if you are able to provide an image (including molecular weight markers) which would help us to asess the results.

    Read More

    For licensing inquiries, please contact partnerships@abcam.com

    Sign up